Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) spanning five years over Washington's request for sensitive information.
This rejection came to light following a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesperson later explained that the United States was seeking genetic material for scientific study and commercial purposes while was not willing to guarantee the benefits from future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further talks to secure a agreement agreeable to both sides so the nation's critical HIV programme can continue.
Wider Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court halted a related health funding agreement following concerns were filed about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government agreements to enhance transparency and responsibility.
As per statements, 16 African countries have to date agreed to similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be available to our people if a new disease outbreak emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining systems already established via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This system is intended to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the independence and interests of both nations."
Medical Community Reaction
Medical experts expressed it recognised the official position, but urged that negotiations need to persist given that a large portion of the country's HIV programmes relied on foreign aid.
"In cases where technical issues arise, such as those relating to data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the complex debate between receiving much-needed international aid and protecting a country's data in an ever more data-driven world.